Vitality Watch

Dossier pubmed review 03-aug-2026
Narrative review or expert overview without new data

Advances in the study of the role of bone immunity in physiological and pathological processes related to bone metabolism.

Key claim: Immune cell networks and immunosenescence drive age-related bone loss through RANKL and inflammatory cytokines, with denosumab, cytokine biologics, and emerging senolytics positioned as bone-protective strategies.

Abstract

BACKGROUND: Bone metabolism is regulated by immune cells that maintain skeletal homeostasis through cytokine secretion and cell interactions. Disruption of this regulation-by inflammation, autoimmunity, or aging-drives pathological bone diseases including osteoporosis and rheumatoid arthritis. Single-cell technologies and exosome biology have revealed previously unrecognized immune subsets and regulatory layers within the bone microenvironment. MAIN BODY: Osteoimmunology has elucidated the interplay between macrophages, T cells, B cells, NK cells, neutrophils, dendritic cells, and mast cells in bone remodeling. These cells form dynamic interaction networks-Treg-M2 feedback loops, Th17-neutrophil amplification, and B-T-osteoclast axes-that collectively determine net skeletal outcome. Immune cells regulate osteoclast and osteoblast function through TNF-α, IL-6, IL-17 A, and RANKL, with highly context-dependent effects. Immunosenescence has emerged as a key driver of age-related bone loss. The RANKL/RANK/OPG axis serves as the central signaling hub, modulated by Sema3A/Wnt/β-catenin, PI3K/Akt, JAK/STAT, and Notch. Dysregulation of these pathways underlies osteoporosis, RA, intervertebral disc degeneration, ankylosing spondylitis, and cancer bone metastasis. Clinically, denosumab and cytokine-targeted biologics (anti-TNF-α, anti-IL-6R, anti-IL-17 A) demonstrate bone-protective effects, while bispecific antibodies, CAR-Treg cells, and senolytics represent emerging strategies. CONCLUSIONS: The net skeletal effect of the immune system is determined by the balance of interacting cell types, cytokine networks, and signaling pathways. Future progress requires single-cell spatiotemporal multi-omics, cell-type-specific immunotherapies, elucidation of the gut-bone axis, and systematic evaluation of combination strategies pairing immunomodulators with anti-resorptives, anabolic agents, or senolytics.

Why this matters

Immune cell networks and immunosenescence drive age-related bone loss through RANKL and inflammatory cytokines, with denosumab, cytokine biologics, and emerging senolytics positioned as bone-protective strategies.

Source

Link

Briefing card

Advances in the study of the role of bone immunity in physiological and pathological processes related to bone metabolism.
Stage: review · pubmed · 03-aug-2026

Immune cell networks and immunosenescence drive age-related bone loss through RANKL and inflammatory cytokines, with denosumab, cytokine biologics, and emerging senolytics positioned as bone-protective strategies.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.intimp.2026.117219

build build 880 · 2bcef25 · 2026-11-18